Navigation Links
New pan-European collaboration launched into the diagnosis and control of coeliac disease
Date:4/9/2008

12 million, equivalent to nearly 9.5 million has been invested by the European Commission into a new pan-European partnership which will design an advanced diagnostic tool for the detection and control of coeliac disease, the most under-diagnosed common chronic condition in the UK today.

The collaborative project, entitled Coeliac Disease Management Monitoring Diagnosis using Biosensors and Integrated Chip Systems (CD-MEDICS), will unite technologies to allow point of care diagnostics, combined with embedded communication technologies to directly interface with hospital information systems. It is expected that the development of the technologies involved and their combination in a single product represent a significant advance in diagnostic technology that has the potential to be applied to the detection of a range of other conditions such, insulin dependent diabetes mellitus or rheumatoid arthritis.

At least 1 in 1001 people in the UK is estimated to suffer from coeliac disease a potentially life-threatening auto-immune condition caused by intolerance to gluten. However, according to a recent study2, only 12.5% of people with the disease are actually being correctly diagnosed. Recent research showed that the average length of time taken for someone to be diagnosed with coeliac disease from the onset of their symptoms is 13 years.

Coeliac disease is not a food allergy but a life-long autoimmune disease caused by intolerance to gluten, a protein found in wheat, barley and rye. For people with coeliac disease, eating gluten damages the lining of the gut, which prevents normal digestion and the absorption of food. There are serious health problems associated with coeliac disease including osteoporosis, gastro-intestinal cancer and increased risk of other autoimmune diseases. The only treatment is a strict gluten-free diet for life. The new diagnostic tool aims to help with early detection and to monitor adherence to the diet.

The project aims to develop a point of care screening device to be implemented at the primary care level. The proposed disposable microchip used to screen for coeliac disease will be used in a portable hand-held device, which will have embedded communication abilities allowing direct storage of test results on a patients electronic medical record. This will enable easy follow-up, management and monitoring of the patients response to withdrawal of gluten from the diet.

The screening device is capable of carrying out multi-analyte tests with the simultaneous detection of coeliac disease associated auto-antibodies (IgA and IgG gliadin, glutenin and tissue transglutaminase) and HLA-DQ2 and DQ8 genes. The analysis of the HLA-DQ2 and DQ8 will give information as to the genetic predisposition of an individual to developing coeliac disease, and the detection of the antibodies will allow for the early diagnosis of coeliac disease (and its recurrence if the gluten-free diet is not complied with).

The pan-European collaboration includes a number of UK-based organisations. Coeliac UK, the charity for people with coeliac disease and Dermatitis Herpetiformis (DH), is leading on training of healthcare professionals about the disease and new technology. Newcastle University is responsible for the development and delivery of the development of a sensing technology platform in the screening device. Researchers at Kings College London will be leading on the development of an anti-glutenin antibody test and the CD MEDICS project is being managed by a company specialising in research project management, iXscient Ltd.


'/>"/>

Contact: Kate Newman
kate.newman@coeliac.org.uk
020-839-97478
Coeliac UK
Source:Eurekalert

Related medicine news :

1. Paving the way for future pan-European clinical trials
2. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
3. American Red Cross and FedEx Announce Collaboration to Help Small Businesses Get Prepared for Disaster
4. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
5. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
6. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
7. London School of Hygiene to play key role in global collaboration on adverse drug reactions
8. Chemizon Announces Research Collaboration Expansion With Takeda
9. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
10. American Diabetes Association Announces Three Year Collaboration With The Dignity Memorial(R) Network
11. Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, and ... 31st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/26/2017)... ... 26, 2017 , ... Somnoware, a leading provider of digital ... its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device integration ... platform, initializing devices and importing studies are just one-click operations. This plugin streamlines ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... Peace Agreements being discussed by President Donald Trump and the rest of the world. ... speed up peace talks in the continuous battle between Israel and Palestine. The world’s ...
(Date:5/26/2017)... Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... Francisco, is proud to announce a new, informational blog post on insurance options. If ... surgery, checking insurance plans may help save time and money. Visiting an in-network provider ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
Breaking Medicine Technology: